clevexelpharma.com
Innovation Days 2016, 3 October | Clevexel
http://www.clevexelpharma.com/innovation
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
CVXL – 0069 | Clevexel
http://www.clevexelpharma.com/cvxl-0069
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
Board of Directors | Clevexel
http://www.clevexelpharma.com/advisory-board
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
Careers | Clevexel
http://www.clevexelpharma.com/careers
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
CVXL – 0107 | Clevexel
http://www.clevexelpharma.com/cvxl-0107
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
CVXL – 0095 | Clevexel
http://www.clevexelpharma.com/cvxl-0095
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
NEWS | Clevexel
http://www.clevexelpharma.com/news
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
Expertise | Clevexel
http://www.clevexelpharma.com/expertise
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.
clevexelpharma.com
Management team | Clevexel
http://www.clevexelpharma.com/management-board
Projet d’introduction en bourse / IPO project. CleveXel is a pharmaceutical company with an innovative business model based on maximizing the marketing potential. Highly specialized, offering a wide array of skills in drug development and clinical research and support. Leadership of a complementary management team with unique pharmaceutical background. CleveXel was created in 2013 by the emanation of the development center from the Cephalon Laboratory (TEVA Group). PARKINSON & CNS DISEASE. April 29, 2016.